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Introduction: There is little information 
in the literature relating supplementary 
oral usage of vitamin D and calcium 
to the development of kidney stones. 
Objective: To evaluate the effect of 
high dose, 200 IU of vitamin D3 (V) 
with calcium supplementation (Ca). 
Methods: Experimental model consists 
of insertion of pellets into the bladder of 
rats. V was administered for 30 days with 
or without Ca. The rats were divided in 
6 groups: 1. Sham, 2. Pellets control; 3. 
V control; 4. Pellets + V; 5. Pellets + Ca 
and 6. Pellets + Ca + V. Results: 50% and 
17% decreases bladder stones formation 
in groups 5 and 6, p < 0.005 comparing 
with the group 2 were observed. There 
was no hypercalcemia or hypercalciuria 
in all groups. We observed a significant 
decrease in calciuria in group 6 (p = 0.03). 
Conclusion: The administration of the V 
associated with Ca significantly decreased 
the formation of stones and caused a 
significant reduction in urinary calcium, 
suggesting a protection in the lithogenic 
pathophysiology.
AbstrAct
Keywords: 25-hydroxyvitamin D 2; nephro-
lithiasis; vitamin D; vitamin D deficiency.
IntroductIon
Urolithiasis is a universal problem. 
The main factors behind urinary stone 
formation and the low hydration of the 
body are: failure of stone formation 
inhibitors as citrate and magnesium, 
urinary pH and increased urinary calcium 
concentration, which affects about 50% 
of patients with kidney stones.1-3
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The risk of developing nephrolithiasis 
is of 10% to 25%;4-6 and it is more 
common in men,7 typically between 30 
and 60 years of age. Incidence increases in 
women in their sixth decade of life, associated 
with increased abdominal circumference, 
tending to an equivalence in both genders.4 
Nephrolithiasis associated with metabolic 
syndrome has been documented, i.e., weight 
gain and increased body mass index (BMI),8 
arterial hypertension,9,10 diabetes mellitus,11,12 
carotid artery atherosclerosis,13 myocardial 
infarction,14,15 with hypocitraturia in 54% 
and hyperuricosuria in 43%.8 Experimental 
studies have demonstrated that Randall plates 
form from the repair of vascular lesions in 
a process similar to atherosclerosis.16 Blood 
flow turbulence in the renal papilla causes 
an inflammation exacerbated by increased 
osmolarity and hypoxia at this site, releasing 
proteins and cytokines that promote crystal 
aggregation.16
Epidemiological studies show that 
patients who develop kidney stones (in 
addition to the metabolic syndrome) 
also have osteopenia/osteoporosis and 
hypovitaminosis D.17 Studies have shown 
that vitamin D deficiency was found in 
about 60% to 80% at the end of the 
winter.18,19 Potential causes for this high 
prevalence are lack of adequate sun 
exposure, risk of developing skin cancer, 
black ethnicity, obesity, age, hospital stay, 
pregnancy, inflammatory bowel disease, 
poor intake of its precursors and the use 
of sunscreen, i.e. SPF 8 sunscreen reduces 
production of vitamin D3 in 95%.
20 
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Sun-exposed skin is the main source, producing 
80% to 90% of the recommended daily doses, 
and the almost total body exposure for 2 minutes 
provides 10,000 IU of vitamin D or exposure of the 
head and neck for 20 minutos.20 Daily vitamin D3 
requirements for children and adolescents is 200 IU 
or 5 µg per day; and 400 IU to 600 IU per day for 
adults. Vitamin D 25OH serum levels of ≥ 30 ng/
ml are considered normal. Concentrations between 
20 and 30 ng/ml are considered insufficient and 
levels < 20 ng/ml indicate vitamin deficiency, using 
the raise in PTH as a reference.20
Vitamin D acts as a hormone in the body. 
1,25(OH)2 vitamin D controls renin and insulin 
secretion21,22 and deficiency is also associated with the 
metabolic syndrome20, including insulin-dependent 
diabetes mellitus and other autoimmune diseases such 
as multiple sclerosis, inflammatory bowel disease, 
systemic lupus erythematosus and rheumatoid arthritis, 
in addition to the increase of infectious diseases, and 
cancer of the colon and prostate, showing that it has 
biological effects far beyond the regulation of bone 
metabolism - which underscores the importance of 
treatment in cases of low vitamin D levels.23
Vitamin D insufficiency treatment is safe 
even at high doses,24 as long as it does not reach 
toxic serum levels of 25(OH) vitamin D - greater 
than 150 ng/ml, resulting in hypercalcemia and 
hyperphosphatemia, which could potentially lead to 
kidney nephrolithiasis.25
Low-calcium diets are associated with the risk 
of bone fractures due to osteoporosis and kidney 
stones.17 There is strong evidence that the best results 
vis-à-vis the prevention of kidney stones are diets 
containing 1,200 mg/day of calcium, accompanied 
by restriction of animal protein, salt and oxalate.26-29 
Calcium intake around 1,500 mg/day in men and 
women can reduce the risk of nephrolithiasis; 
however, recent studies from the WHI show that 
daily oral doses up to 2,150 mg of calcium with 
vitamin D, increase in 17% the risk of developing 
kidney stones.30
The treatment of low vitamin D levels and 
calcium supplementation in patients developing 
kidney stones is a matter to be considered, since 
hypercalcemia and hypercalciuria are risk factors 
for the development of nephrolithiasis, justifying 
this experimental study of nephrolithiasis with an 
overdose of vitamin D and calcium supplementation.
MAterIAls And Methods
Thirty-six adult Wistar rats of 8 weeks of age and 
an average weight of 250 g were placed in individual 
cages. Their newly eliminated urine was collected for 
measuring pH and the 24-hour urine was collected 
for measuring creatinine, sodium, potassium, urine 
specific gravity, calcium and magnesium. We took 
blood samples from all the animals at the beginning 
and end of the experiment for measuring creatinine, 
calcium, sodium, potassium and magnesium. In 
this experimental nephrolithiasis model, we used 
a preformed pellet of calcium oxalate which was 
surgically inserted into the bladder and serves as 
support surface for the precipitation of organic and 
inorganic components, and it may also form satellite 
stones.
The animals were divided into six groups of six 
animals each: group 1 Sham, without manipulation 
or drugs; group 2: control with only the pellet (P) in 
the urinary bladder (P); group 3: control receiving 
only 1 drop orally with 200 IU of vitamin D3 per 
day (V); group 4: P and V; group 5: P and calcium 
(Ca) supplementation 4 mg of calcium carbonate 
diluted in 0.5 ml of water and administered by 
gavage; group 6: P + Ca + V. The animals were 
slaughtered at day 30 under anesthesia and kidney 
perfusion. The kidneys were subjected to histo-
pathological examination with PAS staining. The 
pellets and stones formed were photographed.
The biochemical data was statistically analyzed 
by the paired Student’s t-test, analyzing the results 
at the beginning and end of the experiment for 
each group. The formation of urinary bladder 
stones was analyzed by the curve of events. The 
subject was considered negative in stone forming 
when the pellet showed no crystal deposits; and 
positive when there was growth and/or formation 
of satellite stones. The data was described using 
standard deviation and a p ≤ 0.05 was considered 
significant.
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results
The mean levels of serum 25(OH) D of rats in the 
PV Group was initially (PVi) 9.10 ± 3.41 ng/ml 
and after 30 days of treatment with V, we found 
a substantial increase in final PV (PVf), at a mean 
of 40.36 ± 10.03 ng/ml (*p = 0.0002), as shown in 
Graph 1.
change in serum calcium in groups 1, 2, 3, 4 and 5. 
There was a significant decrease in serum calcium 
in group 6 p = 0.03. Table 1.
We found no significant differences between 
the values of magnesemia and magnesuria at the 
beginning and end of the experiment, analyzing the 
results of all groups at the beginning and end of the 
experiment individually with Student’s paired t test 
(Table 2).
There was no significant change in creatinine 
clearance when we individually analyzed all groups 
applying the Student’s t-test (Table 3).
There was no pH change in freshly eliminated 
urine, urine specific gravity, sodium levels, 
natriuresis and potassiuria when we analyzed the 
results at the beginning and end of the experiment 
by the Student’s paired t-test. There were no 
histopathological changes seen when we analyzed 
the kidneys of all animals from of all groups, 
and we did not find signs of nephrocalcinosis or 
nephrolithiasis (data not shown).
dIscussIon
As noted in the results, there was a lower percentage 
of stone formation in the groups receiving only 
calcium and calcium with vitamin D3. The average 
level of 25(OH) D baseline serum of the rats was 
9.10 ± 3.41 ng/ml, which is in agreement with 
the results in the literature.31-33 After 30 days of 
treatment there was a significant increase in the 
levels of 25(OH) D, reaching 40.36 ± 10.03 ng/ml. 
The dose of 200 IU, that is, 5 µg of vitamin D3 
administered as one oral drop, increased circulating 
levels of 25(OH) D to about 4 times. We expected 
Graph 1. Vitamin D3 concentration in ng/ml Method: Vitamin D total 
Roche; Method: Electrochemiluminescence. Device: Elecsys 2010 
Measuring interval: 3.00-70 ng/ml.
There was a progressive decrease in stone 
formation in the groups receiving 45% V (PV, 
p = 0.138), 55% calcium (PCa, p = 0.05) and 
calcium with V in 17%, which was also significant 
(PCaV, p = 0.005). Graph 2 and Figure 1.
Graph 2. Percentage of stone formation: CP: Control with pellet; 
PV: Pellet + Vitamin D3; PCa: Pellet + calcium supplementation; 
PCaV: Pellet + calcium supplementation + Vitamin D3.
The calcium levels in all groups showed no 
significant difference, comparing the results at 
the beginning and end of the experiment applying 
the paired Student t-test. There was no significant 
Figure 1. Photography of the stones. Group 2; CP: Control 
with pellets; Group 4; PV: Pellet + Vitamin D3; Group 5 
PCa: Pellet + calcium supplementation; Group 6: PCaV: 
Pellet + calcium supplementation + Vitamin D3.
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tAble 1 calcemia and calciuria Of all the animals






1. Sham 9.82 ± 0.45 9.65 ± 0.57 p = 0.64 0.33 ± 0.04 0.38 ± 0.07 p = 0.17
2. CP 9.15 ± 0.37 9.57 ± 0.42 p = 0.83 0.42 ± 0.11 0.36 ± 0.07 p = 0.10
3. CV 9.50 ± 0.24 9.93 ± 1.23 p = 0.42 0.30 ± 0.18 0.34 ± 0.14 p = 0.68
4. PV 9.93 ± 0.61 9.57 ± 0.34 p = 0.23 0.33 ± 0.28 0.47 ± 0.28 p = 0.07
5. PCa 9.90 ± 0.39 10.13 ± 0.33 p = 0.20 0.45 ± 0.13 0.37 ± 0.15 p = 0.14
6. PCaV 10.15 ± 0.30 10.00 ± 0.43 p = 0.45 0.40 ± 0.13 0.21 ± 0.21* *p = 0.03
Calcemia and calciuria, mean with SD. Groups: 1. Sham; 2. CP: Control with pellet; 3. CV: Control Vitamin D3; 4. PV: Pellet + Vitamin D3; 5. PCa: 
Pellet + calcium supplementation; 6. PCaV: Pellet + calcium supplementation + V. Results individually analyzed in the groups at the beginning (i) 
and end (f) of the experiment, employing the Student’s t-test.











1. Sham 2.13 ± 0.19 2.72 ± 0.17 p = 0.10 1.82 ± 0.82 3.44 ± 0.81 p = 0.11
2. CP 2.53 ± 0.16 2.38 ± 0.16 p = 0.19 1.77 ± 1.27 2.31 ± 1.78 p = 0.55
3. CV 2.48 ± 0.29 2.67 ± 0.80 p = 0.63 1.70 ± 1.03 1.99 ± 1.40 p = 0.75
4. PV 2.55 ± 0.40 2.37 ± 0.12 p = 0.28 1.28 ± 0.65 2.63 ± 1.43 p = 0.11
5. PCa 2.31 ± 0.10 2.57 ± 0.31 p = 0.10 2.81 ± 1.38 2.87 ± 1.73 p = 0.82
6. PCaV 2.27 ± 0.27 2.47 ± 0.27 p = 0.19 1.64 ± 1.63 1.70 ± 1.51 p = 0.83
Magnesemia and magnesuria. Groups: 1. Sham; 2. CP: Control with pellet; 3. CV: Control Vitamin D3; 4. PV: Pellet + Vitamin D3; 5. PCa: Pellet + 
calcium supplementation; 6. PCaV: Pellet + calcium supplementation + V. Results were individually analyzed in the groups at the start (i) and end 
(f) of the experiment, employing the Student’s t-test.
tAble 3 creatinine clearance frOm all the animals
Sham i Sham f CV i CV f CP i CP f PV i PV f PCa i PCa f PCaVit i PCaVit f
1.29 1.68 0.96 1.32 0.97 1.43 1.19 1.92 1.43 1.11 1.73 1.63
1.35 1.29 0.77 1.22 1.46 1.19 1.16 1.36 1.00 0.82 1.20 1.26
1.29 1.22 0.85 1.12 0.91 0.92 1.64 1.61 0.98 1.20 1.08 0.91
1.42 1.28 1.60 1.30 0.91 1.76 1.86 1.45 1.04 1.87 1.03 0.82
1.62 1.42 1.50 1.58 1.72 1.53 1.25 1.10 1.31 1.05 1.45 1.42
1.41 1.72 1.21 1.06 0.89 1.26 1.10 1.23 1.68 0.83 1.86 1.81
p = 0.72 p = 0.37 p = 0.29 p = 0.64 p = 0.70 p = 0.09
Creatinine clearance in ml/min. Groups: 1. Sham; 2. CP: Control with pellets; 3. CV: Control Vitamin D3; 4. PV: Pellet + Vitamin D3; 5. PCa: Pellet + 
calcium supplementation; 6. PCaV: Pellet + calcium supplement + V. Results individually analyzed at the beginning (i) and end (f) of the experiment, 
employing the Student’s t-test.
higher blood levels, since the dose of 200 IU for a 
rat of 250 g in weight corresponds to 280 times the 
recommended dosage for an adult of 70 Kg, this is 
equivalent to 50,000 IU daily, which would raise 
serum levels to approximately 150 ng/ml - sufficient 
to cause poisoning in humans.25
Vitamin D3 poisoning classically causes 
hypercalcemia, hypercalciuria, renal failure with 
changing levels of blood and urinary creatinine 
with decreased creatinine clearance,20 which might 
increase the risk of the individual developing 
nephrolithiasis.
In our study, there were no significant changes 
in type 1 urine volume, such as decreased urine 
volume or hematuria, including urinary pH 
values in newly urinated urine, which was carried 
out with the aim of analyzing tubular behavior 
vis-à-vis a possible hypercalciuria, which could 
happen with reduced urinary pH by increasing 
renal excretion of hydrogen and increased calcium 
resorption - mechanisms the kidney has to protect 
itself from the formation of stones.20 Likewise, 
there was no change in creatinine clearance and 
serum calcium, comparing the results at the 
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beginning and end of the experiment. There was 
a significant decrease in urine calcium in group 
6, i.e., calcium supplementation with vitamin D3. 
These results are consistent with an overdose of 
vitamin D and not with poisoning, which allowed 
us to assess the effect vitamin D3 overdose in 
foreign-body lithiasis model in rats.
There may have been some protective mechanism 
in the absorption or metabolism of vitamin D3 
in rats, thus avoiding intoxication. There was 
no constipation or diarrhea, anorexia, apathy, 
gnashing of teeth, impaired coordination, difficulty 
breathing, nasal mucosa exudation or deaths, as 
described in rabbits that received two doses of 52 
mg/kg of subcutaneous vitamin D3 with an interval 
of 4 days, that even had arterial calcification and 
nephrocalcinosis.34 It is interesting to notice that 
a proper vitamin D3 supplementation lowers the 
risk of cardiovascular events; however, in vitamin 
D poisoning just the opposite can occur,34 which 
emphasizes the importance of treating vitamin 
D insufficiency with safe doses and treatment 
monitoring.
In our experiment, the administration of calcium 
significantly decreased the formation of stones  and 
calciuria. There is strong evidence that calcium 
supplementation in the diet reduces the incidence 
of lithiasis.26-28 Sorensen et al.29 conducted a cohort 
study of 10,000 women followed for 20 years, who 
received radioactive calcium. They found a decrease 
in stone formation at least by 45% in patients 
who received calcium supplementation in the diet, 
around 1,500 mg/day compared with patients 
with restriction of dietary calcium. Restriction of 
dietary calcium decreases the ability of this cation 
of forming calcium oxalate salts in the intestinal 
lumen, resulting in increased absorption of oxalate 
and causing increased oxaluria,35 but it is important 
to note that consumption of more than 2,150 mg 
of calcium increases in 17% the risk of developing 
kidney stones.30
In our experiment, the administration of vitamin 
D3 in group 4 reduced stone formation by 50%, but 
not statistically significant (p = 0.138). When only 
calcium supplementation was used (group 5) there 
was a significant 50% decrease - p = 0.05 - in stone 
formation, which decreased further to 17% in group 
6 with the addition of vitamin D3, with p = 0.005.
There is little data in the literature on the 
treatment of low vitamin D and nephrolithiasis. 
A recent publication of a human study by the 
NHANES III36 shows no significant correlation 
between the prevalence of nephrolithiasis and 
serum 25(OH) D levels between those who 
develop stones and those who do not (p = 0.57), 
including the administration of vitamin D3, 
leading to serum levels between 40 and 50 ng/
ml. Serum levels of 25(OH) D were not associated 
with increased risk (OR) of stones in patients 
who develop stones [OR = 0.99; 95% confidence 
interval (CI) 0.99-1.01], with adjustment for age, 
gender, ethnicity, serum calcium levels, history of 
hypertension or diabetes, body mass index and 
the use of diuretics.36 Koul et al.25 reported 10 
cases of poisoning in humans in India. Patients 
receiving high doses of vitamin D3 for 2 to 4 
months developed hypercalcemia, hypercalciuria, 
and decreased creatinine clearance, but none had 
nephrolithiasis upon the ultrasound exam.
Although the uptake of 1200-1500 mg of calcium 
per day may reduce the incidence of lithiasis, 
the treatment of low vitamin D at doses above 
physiological requires follow-up and monitoring of 
the vitamin D (25OH) dose, particularly in patients 
who develop stones. More studies are needed in 
this regard, especially about the curious association 
between metabolic syndrome, nephrolithiasis and 
low serum vitamin D.
conclusIon
In this protocol, the administration of high 
doses of vitamin D3 associated with calcium 
supplementation significantly decreased the 
development of kidney stones and coursed with a 
significant decrease in serum calcium, suggesting 
a protection in the pathophysiology of kidney 
stones in rats. The treatment of low vitamin D 
with vitamin D3 and calcium supplementation 
in appropriate doses might benefit patients who 
develop stones.
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